CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Supplementary Table. Baseline Demographic and Disease Characteristics of Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) and Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR) Study Participants — United States and International Sites, 2021–2022
-
12/22/2023
-
Source: MMWR: Morbidity and Mortality Weekly Report 2023; v. 72, no. 51
[PDF-200.40 KB]
Details:
-
Alternative Title:Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022: Supplementary Table. Baseline Demographic and Disease Characteristics of Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) and Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR) Study Participants — United States and International Sites, 2021–2022
-
Corporate Authors:
-
Source:
-
Series:
-
ISSN:0149-2195 (print);1545-861X (digital);
-
Document Type:
-
Place as Subject:
-
Pages in Document:2 pdf page
-
Volume:72
-
Issue:51
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: